Severe Asthma in School-Age Children: An Updated Appraisal on Biological Options and Challenges in This Age Group DOI Creative Commons
Cristiana Indolfi, Angela Klain,

Marina Capuano

et al.

Children, Journal Year: 2025, Volume and Issue: 12(2), P. 167 - 167

Published: Jan. 29, 2025

This review examines the growing role of biological therapies in managing severe asthma children aged 6–11 years. Severe asthma, characterized by persistent symptoms and frequent exacerbations, presents significant challenges pediatric care. Biologic treatments, including mepolizumab, omalizumab, dupilumab, provide targeted interventions for patients with high eosinophilic inflammation or allergic (T2-high asthma). Alongside their therapeutic benefits, evaluates safety profiles these biologics, highlighting potential side effects necessity monitoring during long-term use. Cost considerations treatment adherence also emerge as important that need to be addressed clinical practice. Additionally, emphasizes identifying who would derive most benefit from biologic therapies, advocating development biomarkers aid decisions. Emerging such tezepelumab, are introduced promising alternatives target upstream inflammatory pathways, offering hope treating T2-low forms, which currently lack effective options children.

Language: Английский

Severe Asthma in School-Age Children: An Updated Appraisal on Biological Options and Challenges in This Age Group DOI Creative Commons
Cristiana Indolfi, Angela Klain,

Marina Capuano

et al.

Children, Journal Year: 2025, Volume and Issue: 12(2), P. 167 - 167

Published: Jan. 29, 2025

This review examines the growing role of biological therapies in managing severe asthma children aged 6–11 years. Severe asthma, characterized by persistent symptoms and frequent exacerbations, presents significant challenges pediatric care. Biologic treatments, including mepolizumab, omalizumab, dupilumab, provide targeted interventions for patients with high eosinophilic inflammation or allergic (T2-high asthma). Alongside their therapeutic benefits, evaluates safety profiles these biologics, highlighting potential side effects necessity monitoring during long-term use. Cost considerations treatment adherence also emerge as important that need to be addressed clinical practice. Additionally, emphasizes identifying who would derive most benefit from biologic therapies, advocating development biomarkers aid decisions. Emerging such tezepelumab, are introduced promising alternatives target upstream inflammatory pathways, offering hope treating T2-low forms, which currently lack effective options children.

Language: Английский

Citations

0